文献速递流行病学与生物统计基础与转化研究

体型与体成分和特定部位癌症风险的孟德尔随机化研究

Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study.
PubMed 文献 · PLoS Med · 2021-07-29

该研究利用孟德尔随机化方法,在UK Biobank 367,561人中评估BMI、脂肪质量指数、去脂体重指数和身高与22种特定部位癌症及总体癌症的关联,并在国际联盟数据中验证肺癌、乳腺癌、卵巢癌、子宫癌和前列腺癌。遗传预测的BMI与总体癌症及消化系统癌症风险正相关,身高与总体及多种部位癌症风险正相关,BMI对性别特异性癌症效应方向不一致。

要点

  • 遗传预测BMI升高增加消化系统癌症风险,对非消化系统癌症无显著关联
  • 遗传预测身高增加与总体癌症及多种部位癌症风险正相关
  • BMI与子宫癌风险正相关、与前列腺癌风险负相关,联盟数据还显示与乳腺癌负相关

核心结论

  • BMI作为癌症因果风险因素的证据混杂:对消化系统癌症有一致因果作用,对性别特异性癌症效应方向不一致
  • 身高增加对总体及部位特异性癌症呈现一致的风险增加效应

研究设计与样本

  • 孟德尔随机化研究,使用SNPs作为工具变量:BMI 312个、FMI 577个、FFMI 577个、身高293个
  • 在UK Biobank 367,561人中评估22种特定部位癌症及总体癌症,并在国际联盟数据中评估肺癌、乳腺癌、卵巢癌、子宫癌和前列腺癌

主要发现

  • UKBB中遗传预测BMI每增加1 kg/m2:总体癌症OR 1.01(95%CI 1.00-1.02;p=0.043)、胃癌OR 1.13(1.06-1.21;p<0.001)、食管癌OR 1.10(1.03-1.17;p=0.003)、肝癌OR 1.13(1.03-1.25;p=0.012)、胰腺癌OR 1.06(1.01-1.12;p=0.016)、肺癌OR 1.08(1.04-1.12;p<0.001)
  • UKBB中遗传预测BMI每增加1 kg/m2:子宫癌OR 1.10(1.05-1.15;p<0.001)、前列腺癌OR 0.97(0.94-0.99;p=0.009)
  • UKBB中遗传预测BMI每增加1 kg/m2:消化系统癌症OR 1.04(1.02-1.06;p<0.001),非消化系统癌症OR 1.01(0.99-1.02;p=0.369)
  • UKBB中遗传预测身高每增加1个标准差:总体癌症OR 1.09(95%CI 1.05-1.12;p<0.001)
  • 联盟数据证实BMI与肺癌、子宫癌正相关及与前列腺癌负相关,并显示BMI与乳腺癌负相关

临床怎么用

  • BMI升高与消化系统癌症风险的因果证据较为一致,提示体重管理可能有助于降低相关癌症风险
  • 身高作为不可干预因素与多种癌症风险正相关,可用于风险分层参考
  • BMI对前列腺癌和乳腺癌的负相关提示需避免将BMI简单视为所有癌症的统一风险因素

局限性

  • 假设遗传变异与癌症结局的关联通过所提出的风险因素介导
  • 部分较低频率癌症类型的效应估计精度较低

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence for the impact of body size and composition on cancer risk is limited. This mendelian randomisation (MR) study investigates evidence supporting causal relationships of body mass index (BMI), fat mass index (FMI), fat-free mass index (FFMI), and height with cancer risk. METHODS AND FINDINGS: Single nucleotide polymorphisms (SNPs) were used as instrumental variables for BMI (312 SNPs), FMI (577 SNPs), FFMI (577 SNPs), and height (293 SNPs). Associations of the genetic variants with 22 site-specific cancers and overall cancer were estimated in 367,561 individuals from the UK Biobank (UKBB) and with lung, breast, ovarian, uterine, and prostate cancer in large international consortia. In the UKBB, genetically predicted BMI was positively associated with overall cancer (odds ratio [OR] per 1 kg/m2 increase 1.01, 95% confidence interval [CI] 1.00-1.02; p = 0.043); several digestive system cancers: stomach (OR 1.13, 95% CI 1.06-1.21; p < 0.001), esophagus (OR 1.10, 95% CI 1.03, 1.17; p = 0.003), liver (OR 1.13, 95% CI 1.03-1.25; p = 0.012), and pancreas (OR 1.06, 95% CI 1.01-1.12; p = 0.016); and lung cancer (OR 1.08, 95% CI 1.04-1.12; p < 0.001). For sex-specific cancers, genetically predicted elevated BMI was associated with an increased risk of uterine cancer (OR 1.10, 95% CI 1.05-1.15; p < 0.001) and with a lower risk of prostate cancer (OR 0.97, 95% CI 0.94-0.99; p = 0.009). When dividing cancers into digestive system versus non-digestive system, genetically predicted BMI was positively associated with digestive system cancers (OR 1.04, 95% CI 1.02-1.06; p < 0.001) but not with non-digestive system cancers (OR 1.01, 95% CI 0.99-1.02; p = 0.369). Genetically predicted FMI was positively associated with liver, pancreatic, and lung cancer and inversely associated with melanoma and prostate cancer. Genetically predicted FFMI was positively associated with non-Hodgkin lymphoma and melanoma. Genetically predicted height was associated with increased risk of overall cancer (OR per 1 standard deviation increase 1.09; 95% CI 1.05-1.12; p < 0.001) and multiple site-specific cancers. Similar results were observed in analyses using the weighted median and MR-Egger methods. Results based on consortium data confirmed the positive associations between BMI and lung and uterine cancer risk as well as the inverse association between BMI and prostate cancer, and, additionally, showed an inverse association between genetically predicted BMI and breast cancer. The main limitations are the assumption that genetic associations with cancer outcomes are mediated via the proposed risk factors and that estimates for some lower frequency cancer types are subject to low precision. CONCLUSIONS: Our results show that the evidence for BMI as a causal risk factor for cancer is mixed. We find that BMI has a consistent causal role in increasing risk of digestive system cancers and a role for sex-specific cancers with inconsistent directions of effect. In contrast, increased height appears to have a consistent risk-increasing effect on overall and site-specific cancers.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Vithayathil M, Carter P, Kar S, et al. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study. PLoS Med. 2021. PMID: 34324486. doi:10.1371/journal.pmed.1003706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。